N-Hexanoic-Tyr-Ile-(6)-Aminohexanoic Amide and the HGF/c-Met Pathway in Synaptic Plasticity

Dihexa represents one of the most aggressively marketed peptide compounds in the nootropic community—a status earned almost entirely on the strength of a single mechanistic claim: that it is 10 million times more potent than BDNF at promoting synaptogenesis. This claim has propagated through biohacking forums, podcasts, and supplement retailers with remarkable velocity and minimal scrutiny. What the claim actually measures, what it does not measure, and what we can and cannot conclude from it are three separate questions. This article examines each with unflinching attention to evidence quality, mechanism, and the cancer-related safety concerns that the nootropic literature consistently downplays or ignores.

Dihexa is a synthetic peptidomimetic derived from angiotensin IV, developed at Washington State University by Joseph Harding and colleagues. It is designed to potentiate signaling through the HGF (hepatocyte growth factor)/c-Met receptor pathway—a mechanism with genuine scientific interest in neurobiology. However, the same pathway is dysregulated in multiple human cancers. The compound’s popularity rests entirely on preclinical animal studies, with zero human pharmacokinetic data, zero Phase I safety trials, and zero clinical efficacy data. This article separates mechanism from marketing, quantifies the evidence gaps, and provides honest guidance on the current state of knowledge.

Contents

↑ Back to contents

• Quick Facts
• What Is Dihexa?
• Origins and Discovery
• Mechanism of Action
• Key Research Areas
• Claims vs Evidence
• Human Evidence Landscape
• Safety, Risks, and Limitations
• Legal and Regulatory Status
• Research Protocols
• Dosing in Published Research
• Dosing in Self-Experimentation
• Frequently Asked Questions
• Related Peptides
• Summary
• References
• Further Reading
• Disclaimer

Quick Facts

↑ Back to contents

What Is Dihexa?

↑ Back to contents

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a small synthetic peptide compound designed to mimic and amplify signaling through a specific growth factor receptor pathway in the brain. It is not a naturally occurring hormone, not an endogenous peptide, and not a compound found in human or animal tissue under physiological conditions. It is a laboratory-created molecule with a specific chemical structure engineered to interact with the HGF (hepatocyte growth factor) receptor, known as c-Met.

The compound belongs to a class of research chemicals known as peptidomimetics—synthetic molecules designed to behave like peptides but with modified structures that may offer advantages such as resistance to enzymatic degradation or enhanced cellular penetration. Dihexa was developed through rational drug design, building on a natural signaling molecule (angiotensin IV) and retaining the key binding and activation properties while altering peripheral features.

In practical terms, Dihexa is sold as a research chemical or nootropic compound—never as a pharmaceutical product, never as an FDA-approved medication, and in most jurisdictions, not as a dietary supplement (which would trigger FDA oversight). It is marketed primarily through nootropic retailers, biohacking communities, and online suppliers, often with claims that far outpace the existing evidence base.

Origins and Discovery

↑ Back to contents

Dihexa was developed at Washington State University (WSU) in the laboratory of Joseph Harding, a neuropharmacologist with a long research career focused on brain neuropeptides and their therapeutic potential. The compound was first described in peer-reviewed literature in 2010, with the landmark potency study appearing in the Journal of Pharmacology and Experimental Therapeutics in 2013. The original scientific motivation was to explore how angiotensin IV—a naturally occurring breakdown product of the hormone angiotensin II—influences memory and synaptic plasticity, and whether engineered derivatives could amplify those effects.

Angiotensin IV itself had already demonstrated memory-enhancing effects in rodent studies dating back to the 1990s. Harding’s group hypothesized that these effects operated through a previously uncharacterized mechanism: potentiation of HGF signaling via the c-Met receptor. To test this, they synthesized a series of modified angiotensin IV analogs and screened them for potency in promoting synaptogenesis (the growth of new synaptic connections) in cultured hippocampal neurons.

Dihexa emerged from this screening as the most potent compound. In hippocampal neuron cultures, extremely low concentrations—in the picomolar to femtomolar range (trillionths to quadrillionths of a mole per liter)—induced detectable increases in synaptogenesis. When the researchers compared the concentration required for half-maximal effect (EC₅₀) for Dihexa to the EC₅₀ for BDNF (brain-derived neurotrophic factor, a well-characterized and widely studied growth factor), they observed a difference of roughly 7 orders of magnitude. This was where the “10 million times more potent” claim originated.

The WSU work also demonstrated that Dihexa could improve spatial learning in rodent models of scopolamine-induced amnesia, and enhanced memory performance in aged rats—findings consistent with the hypothesis that HGF/c-Met pathway activation might have cognitive benefits. However, the gap between in vitro potency measurements and in vivo behavioral outcomes remained unexplored in humans. By design, it still is.

Mechanism of Action

↑ Back to contents

The HGF/c-Met Pathway in Synaptogenesis

Dihexa’s proposed mechanism centers on the hepatocyte growth factor (HGF) receptor signaling pathway, also known as the c-Met pathway. In normal neurobiology, HGF is a secreted protein that binds to the c-Met receptor—a tyrosine kinase receptor found on neurons and glial cells. When HGF binds to c-Met, it triggers a cascade of intracellular signaling events that promote cell growth, survival, migration, and—importantly for neuroscience—synapse formation.

HGF/c-Met signaling is particularly important during brain development and in response to injury. It promotes the outgrowth of neurites (axons and dendrites), supports the formation of stable synaptic connections, and enhances synaptic plasticity—the ability of neurons to modify their connections in response to experience. This is the molecular basis of learning and memory. In aged brains or brains exposed to cognitive insults (like scopolamine-induced amnesia in rodent models), HGF/c-Met signaling is relatively downregulated; enhancing it could theoretically restore some degree of synaptic plasticity.

Dihexa was designed to enhance this pathway by promoting the interaction between HGF and c-Met, or by mimicking HGF’s signaling capacity at lower concentrations. The mechanism is not fully elucidated—it remains unclear whether Dihexa acts as a direct c-Met agonist, a HGF analog, a potentiator of HGF signaling, or something else. The original papers do not provide exhaustive mechanistic detail. What is clear from the in vitro work is that Dihexa, at very low concentrations, activates signaling cascades downstream of c-Met (phosphorylation of Akt, ERK, and other kinases) and promotes the growth and stabilization of dendritic spines and synaptic connections.

In Vitro vs. In Vivo: The Critical Distinction

It is essential to separate what Dihexa does in cultured neurons (in vitro) from what it might do in an intact brain (in vivo). In vitro studies use isolated hippocampal neurons grown in culture dishes, bathed in controlled media, with no blood-brain barrier, no competing signaling pathways, no metabolic variability, and no immune system. When you add Dihexa to such a culture at picomolar concentrations, you observe measurable increases in synaptogenesis. This is reproducible, quantifiable, and publishable.

In vivo studies use whole animals—live rats whose brains are intact, whose bodies metabolize drugs, whose blood-brain barriers filter compounds, and whose cognitive outcomes are measured through behavioral tests (water mazes, fear conditioning, novel object recognition). The WSU group demonstrated that Dihexa improved spatial learning in rodent amnesia models and enhanced memory in aged rats. This is valuable, but it does not establish that Dihexa works through the same mechanism in vivo as in vitro, that it reaches the brain in meaningful concentrations, or that it engages the c-Met pathway in living neural tissue.

There have been no pharmacokinetic (PK) studies of Dihexa in rodents, and certainly none in humans. We do not know how much of an orally administered dose reaches the bloodstream, how much crosses the blood-brain barrier, how it is metabolized, or what the elimination half-life is. We do not know whether doses used in behavioral experiments actually achieve picomolar concentrations in relevant brain regions. This gap is not a minor detail—it is central to interpreting the evidence.

Key Research Areas

↑ Back to contents

Spatial Learning and Memory (Rodent Models)

The most commonly cited behavioral study appears in the original 2013 JPET paper. Researchers administered Dihexa to rats in a water maze task (Morris water maze), a standard test of spatial learning and memory. Dihexa-treated rats showed improved performance compared to controls. Similar improvements were observed in a passive avoidance task and in a scopolamine-induced amnesia model, where an anticholinergic drug is used to impair memory formation.

Follow-up work has applied Dihexa to aged rat models. Cognitive decline is a hallmark of aging, and spatial learning tasks are particularly sensitive to age-related deficits. Dihexa administration partially reversed these deficits, consistent with the hypothesis that enhancing HGF/c-Met signaling could restore synaptic plasticity in aging.

Synaptogenesis and Dendritic Spine Density

In hippocampal neuronal cultures, Dihexa increased the number and size of dendritic spines—the small protrusions that form the physical substrate of synaptic connections. This occurred at concentrations as low as 10^-15 to 10^-17 M (femtomolar to attomolar). The effect was blocked by inhibitors of c-Met signaling, supporting the conclusion that the effect is mediated through that pathway.

Quantitative analysis showed that Dihexa was 5–10 million times more potent than BDNF at promoting synaptogenesis, as measured by EC₅₀ values. This is the origin of the “10 million times” claim. However, it bears repeating: this comparison is made in a controlled in vitro system using a single molecular readout, not in a human brain, not at a behavioral level, and not under any condition relevant to clinical use.

Mechanism Confirmation Studies

Subsequent studies have confirmed that Dihexa’s synaptogenic effects depend on c-Met activation. Blocking c-Met with selective inhibitors (such as crizotinib, a c-Met antagonist used in cancer therapy) abolishes Dihexa’s effects on spine growth and synaptogenesis. This supports the proposed mechanism but does not confirm that the pathway is engaged the same way in vivo or in humans.

Some work has explored downstream signaling: Dihexa activates PI3K/Akt and MAPK/ERK pathways, known intracellular cascades that promote synaptic growth and stability. However, these are generic signaling cascades—they are activated by many growth factors and neuromodulators, and their activation alone does not prove functional cognitive benefit.

Common Claims versus Current Evidence

↑ Back to contents

Human Evidence Landscape

↑ Back to contents

There are zero human studies of Dihexa.

This is not hyperbole. There are no published Phase I safety trials, no pharmacokinetic studies, no efficacy trials, no dose-finding studies, and no case reports in the peer-reviewed medical literature. No human has ever received Dihexa in a controlled research setting with systematic monitoring of blood levels, biomarkers, cognitive outcomes, or adverse events. This statement stands as of the knowledge cutoff for this article and based on searches of PubMed, Google Scholar, and the NIH clinical trials registry.

The nootropic and biohacking communities have conducted numerous self-experimentation studies, producing anecdotal reports, blog posts, and social media testimonials. These are not evidence in any scientific sense. They are subject to massive placebo effects, confirmation bias, unmeasured confounding variables, recall bias, and publication bias (people who had positive experiences are far more likely to post about them). Some self-experimenters have attempted to measure cognitive outcomes using online cognitive testing platforms or wearable biomarkers, but none of these efforts have been peer-reviewed, blinded, or controlled.

The complete absence of human data means:

• We do not know whether Dihexa is absorbed from the gastrointestinal tract at all.
• We do not know whether any absorbed compound crosses the blood-brain barrier.
• We do not know the half-life, clearance rate, or metabolic fate of Dihexa in human plasma or tissue.
• We do not know whether it engages c-Met signaling in the human central nervous system.
• We do not know what dose, if any, would be necessary to achieve behavioral effects in humans.
• We do not know the frequency or severity of adverse events in humans.
• We do not know whether cognitive effects observed in rodent models would translate to humans.

The last point deserves emphasis. Rodent cognition is measured through behavioral paradigms (mazes, fear conditioning, novel object recognition) that are assumed to correlate with learning and memory. Humans have vastly more complex cognition, different neural architecture (particularly in the prefrontal cortex), different life experience, and different baseline plasticity. Compounds that enhance memory in aging rats do not automatically improve human cognition. The translation gap is enormous.

Safety, Risks, and Limitations

↑ Back to contents

The Cancer Risk Concern

The most serious safety concern surrounding Dihexa is rarely discussed in the nootropic literature, and when it is mentioned, it is often dismissed without rigorous analysis. This concern centers on the HGF/c-Met pathway itself.

The c-Met receptor is a proto-oncogene—a normal cellular gene whose mutation or overexpression is associated with oncogenic transformation (the process by which normal cells become cancerous). Dysregulation of c-Met signaling is implicated in the pathogenesis of multiple human malignancies, including gastric cancer, lung cancer, hepatocellular carcinoma, breast cancer, and glioblastoma (brain cancer). In many of these cancers, c-Met becomes hyperactive through gene amplification, point mutations, or paracrine/autocrine stimulation by HGF.

The mechanism is well-established: c-Met activation promotes cell proliferation, survival, motility, and invasiveness—the hallmarks of malignant behavior. Pharmacological c-Met inhibitors (such as crizotinib) are used as anticancer agents, precisely because blocking this pathway impairs cancer cell growth.

Now consider the inverse proposition: chronic activation of c-Met signaling by Dihexa could theoretically enhance cancer cell proliferation, survival, and invasiveness. While the nootropic community often asserts that “Dihexa promotes synaptogenesis in neurons” as if this were its only effect, c-Met is expressed on multiple cell types—fibroblasts, endothelial cells, immune cells, and yes, cancer cells. If Dihexa systemically enhances c-Met signaling, it could potentially benefit cancer cells as well as neurons.

Has this been studied? No. Has it been formally addressed in any Dihexa paper? No. Has it been dismissed as theoretical scaremongering? Frequently. But “we have not tested it” is not the same as “it is safe.” In the absence of in vivo toxicology studies, chronic dosing studies, and mechanistic examination of c-Met activation in non-neural tissues, the cancer risk remains a theoretical but plausible concern.

This is particularly worrisome for long-term self-experimentation in the nootropic community. Individuals taking Dihexa for months or years have no systematic monitoring of tumor markers, imaging, or any biomarker of oncogenic risk. If a latent cancer were to develop, the causal connection to Dihexa would be difficult to establish and would likely be missed.

Absence of Toxicity Data

Beyond the c-Met concern, there are simply no toxicology studies of Dihexa. We do not know:

• The acute toxicity (LD₅₀) in any species
• The target organ of toxicity, if any
• Whether there are dose-dependent or duration-dependent toxic effects
• Whether Dihexa is genotoxic, mutagenic, or teratogenic
• Whether it causes histological changes in any organ at chronic doses
• The mechanism of any adverse effects that might occur

The original published studies mention that rats receiving Dihexa showed no “gross behavioral abnormalities” or “visible signs of distress,” but this is not systematic toxicology. It is casual observation. Lack of overt behavioral changes does not rule out subclinical organ damage, metabolic disruption, or long-term carcinogenic potential.

Peptide Stability and Immunogenicity

Dihexa is a small peptide-like molecule. Peptides are generally susceptible to enzymatic degradation by proteases in the bloodstream and gastrointestinal tract. The claim that Dihexa has oral bioavailability is unusual and has not been verified by formal PK studies. If bioavailability is indeed high (as claimed), the question arises: why? Does Dihexa have some structural modification that confers protease resistance? Is it protected by binding to carrier proteins? Or is the bioavailability claim simply incorrect?

Additionally, repeated administration of peptide-like compounds can trigger immune responses—the formation of anti-Dihexa antibodies that neutralize the compound and potentially cause systemic inflammation or hypersensitivity reactions. This has never been systematically studied.

Interactions with Other Compounds

There are no published drug-drug interaction studies, no food-drug interaction studies, and no studies examining how Dihexa interacts with other growth factors, cytokines, or neurotrophic factors that users might be taking (such as BDNF-promoting compounds, corticosteroids, or other peptides). In principle, concurrent c-Met activation by multiple mechanisms could produce unexpectedly strong effects. In practice, we do not know.

Off-Target Effects

The original characterization of Dihexa’s mechanism focused on c-Met activation. However, peptide-like molecules often have multiple receptor interactions—off-target effects that are not initially characterized. Dihexa could plausibly interact with other receptors in the angiotensin signaling family (AT1, AT2, AT4) or with other growth factor pathways. These effects have not been systematically mapped.

Individual Variability

Even if Dihexa were safe on average, there could be subpopulations at higher risk due to genetics, existing health conditions, or medications. For example, individuals with c-Met mutations, cancer predisposition syndromes, or active malignancy might be at substantially higher risk. Individuals taking immunosuppressive drugs or chemotherapy might have unpredictable interactions. Without human studies, these subgroups cannot be identified or counseled.

Legal and Regulatory Status

↑ Back to contents

FDA Status

Dihexa is not approved by the FDA and is not authorized for human use in the United States. It has never undergone IND (Investigational New Drug) review, has never entered any phase of clinical trials under FDA oversight, and has never been evaluated by the FDA for safety or efficacy in humans. As of this writing, there is no pending NDA (New Drug Application) or ANDA (Abbreviated New Drug Application).

Dihexa is sold as a “research chemical” or “nootropic supplement” in a regulatory gray zone. It does not meet the definition of a dietary supplement under DSHEA (Dietary Supplement Health and Education Act) because it is a synthetic compound not derived from a food source and making drug-like claims. It is therefore technically an unapproved drug under FDA regulations. However, the FDA has limited enforcement resources and has not systematically targeted Dihexa retailers, likely because the compound has not been associated with hospitalization-level adverse events and public awareness remains low.

WADA Status

Dihexa is not on the WADA (World Anti-Doping Agency) Prohibited List. Athletes competing in sports under WADA jurisdiction can use Dihexa without technical violation of anti-doping rules. However, this does not mean it is approved for athletic use or safe for that purpose. WADA lists are designed to target compounds with performance-enhancing potential in specific contexts. Dihexa’s omission likely reflects low recognition among sports governing bodies and the absence of human data demonstrating athletic enhancement, not a judgment that it is safe or effective.

International Regulatory Landscape

Dihexa’s regulatory status varies internationally. In most countries, it is unregulated and freely available for purchase as a research chemical. In some jurisdictions, it may be subject to restrictions on unapproved drugs or novel psychoactive substances, but enforcement is inconsistent. Canada, Australia, and the European Union do not have specific classifications or restrictions for Dihexa, though selling it as a supplement or therapeutic would violate regulations in those jurisdictions as well.

Implications for Users

The regulatory gray zone means that Dihexa users have no legal recourse if the compound is contaminated, mislabeled, or causes harm. There is no inspection of manufacturing facilities, no quality control requirements, no potency verification, and no impurity testing. A vial purchased online could contain pure Dihexa, a mixture of Dihexa and inactive ingredients, a completely different compound, or a contaminant. This is not speculation—it has been documented for other nootropic compounds through laboratory analysis.

Research Protocols

↑ Back to contents

In Vitro (Neuronal Culture) Studies

Standard Protocol Overview: Hippocampal neurons are isolated from embryonic rodent brain tissue (typically E18 rats or E19 mice), dissociated, and cultured on glass coverslips or multiwell plates coated with poly-D-lysine and laminin. Cells are maintained in serum-free neurobasal medium supplemented with B27 and glutamine. At 7–14 days in vitro (DIV), cultures have developed mature synaptic connections.

Dihexa Treatment: Dihexa is added directly to culture media at concentrations ranging from 10^-17 M to 10^-12 M (attomolar to picomolar). Cultures are incubated for 24–72 hours. Control wells receive vehicle (typically DMSO) at matching concentrations.

Readouts: Synaptogenesis is quantified by immunofluorescence microscopy. Dendritic spines are visualized using anti-PSD-95 (postsynaptic density protein) and anti-synapsin (presynaptic marker) antibodies. Spine density, spine volume, and synaptic puncta density are measured using automated image analysis. EC₅₀ values (the concentration producing half-maximal effect) are calculated using curve-fitting software.

Key Finding: Dihexa displays an EC₅₀ in the low femtomolar range (10^-15 to 10^-16 M) for promoting synaptogenesis, approximately 10⁷-fold lower than BDNF’s EC₅₀.

Mechanism Confirmation: Parallel experiments use selective c-Met inhibitors (e.g., PF-04217903, crizotinib) or HGF-blocking antibodies. These antagonists abolish Dihexa’s synaptogenic effects, supporting c-Met-dependent mechanism.

In Vivo (Behavioral) Studies in Rodents

Standard Protocol Overview: Adult or aged male Sprague-Dawley or F344 rats are used. Dihexa is administered via oral gavage (typically 1–10 µg/kg), intraperitoneal injection, or intravenous injection. Dosing frequency varies from acute (single dose) to chronic (daily for 7–28 days).

Morris Water Maze (Spatial Learning): Rats are trained to locate a submerged platform in a circular pool of opaque water over 4–5 days (acquisition phase). The platform location is then moved or removed (probe trials), and the rat’s search strategy is recorded via automated tracking. Time to platform, path length, and time spent in the target quadrant are measured. Dihexa-treated rats typically show reduced latency (faster learning) and increased target zone occupancy (better memory).

Passive Avoidance (Fear-Based Memory): Rats are placed in a light chamber; crossing to a dark chamber triggers a mild footshock. On a subsequent test, latency to enter the dark chamber is measured—longer latency indicates better memory of the shock-associated context. Dihexa treatment increases latency compared to vehicle control.

Scopolamine-Induced Amnesia: Scopolamine (a muscarinic antagonist) is used to impair memory formation. Dihexa is administered prior to scopolamine treatment, and cognitive performance on water maze or passive avoidance tasks is measured. Dihexa partially reverses scopolamine-induced deficits, suggesting a memory-enhancing effect.

Key Findings: Across multiple behavioral paradigms, Dihexa-treated animals outperform vehicle-treated controls, with effect sizes typically 20–50% improvement in task performance.

Dosing and Pharmacokinetics

Notably, no formal PK studies (measuring blood levels, brain penetration, half-life, clearance) have been published for Dihexa in any species. Doses used in behavioral studies are inferred from in vitro EC₅₀ values and adjusted empirically. The assumption is that higher doses lead to higher systemic and brain exposure, but this has never been validated through direct measurement.

Dosing in Published Research

↑ Back to contents

Dosing in Self-Experimentation

↑ Back to contents

Dosing Considerations and Concerns

Lack of PK Data: Without pharmacokinetic studies, there is no way to know whether oral doses of 50 µg to 1 mg result in plasma concentrations that bear any relationship to the in vitro EC₅₀ values or the rodent behavioral doses. Self-experimenters may be vastly underdosing, vastly overdosing, or somewhere in between—and they have no way to know.

Route-Dependent Variability: Intranasal and subcutaneous routes are touted as “better” for brain penetration, but this is not based on any Dihexa data. For most peptides, intranasal delivery is unreliable and inconsistent. Some claims about intranasal c-Met activators penetrating the blood-brain barrier are inferred from theoretical advantages, not empirical evidence.

Tolerance and Desensitization: Chronic activation of the c-Met pathway could theoretically trigger receptor desensitization—a process wherein repeated exposure to a signaling molecule causes the receptor to become less responsive. This is common with growth factors and neuropeptides. If desensitization occurs, effects could wane over weeks or months of continuous dosing. This has never been studied in Dihexa users or even in chronically treated animals.

Cycling and Washout: Some self-experimenters employ dosing cycles (e.g., 4 weeks on, 2 weeks off) based on the hypothesis that this prevents tolerance. This is rational but unvalidated. The washout period needed (if any) to restore c-Met receptor sensitivity is unknown.

Frequently Asked Questions

↑ Back to contents

Related Peptides and Comparative Overview

↑ Back to contents

Dihexa is one of several synthetic peptides or peptide-derived compounds marketed as cognitive enhancers in the nootropic sphere. The following table provides comparative context.

Comparative Summary: Among these compounds, Cerebrolysin has the most extensive human clinical trial data, though results are mixed and mechanism is poorly understood. Semax has some human clinical experience and may have slightly better evidence for efficacy. P21 is the least studied. Dihexa is positioned as the most mechanistically specific (HGF/c-Met pathway) and the most potent in vitro, but has zero human data and a theoretical cancer risk concern that the others do not share. In terms of evidence quality, the ordering from strongest to weakest would be: Cerebrolysin ≈ Semax > P21 > Dihexa. None of these compounds should be considered as equivalent to FDA-approved, well-characterized cognitive enhancers.

Summary

↑ Back to contents

Dihexa is a synthetic peptidomimetic derived from angiotensin IV, developed at Washington State University to potentiate HGF/c-Met signaling and promote synaptogenesis. In vitro, it displays remarkable potency—promoting synaptic growth at picomolar concentrations, approximately one-ten-millionth the concentration of BDNF. This is the origin of the “10 million times more potent” claim, which is scientifically accurate as a narrow in vitro EC₅₀ measurement but is routinely misrepresented as evidence of superior whole-organism potency, safety, or cognitive benefit.

In rodent models, Dihexa improves spatial learning and memory. However, these studies did not establish that Dihexa crosses the blood-brain barrier, does so in meaningful concentrations, or engages c-Met signaling in living rodent brains. The gap between in vitro potency and in vivo mechanism remains bridged only by assumption.

The fundamental problem is the complete absence of human data. Zero pharmacokinetic studies. Zero Phase I safety trials. Zero dose-finding studies. Zero efficacy trials. Zero case series. This is not a limitation that future research will overcome—it is the current state of knowledge, and anyone claiming otherwise is misleading you.

The safety landscape is particularly concerning. c-Met is a proto-oncogene dysregulated in multiple human cancers. Chronic c-Met pathway activation could theoretically enhance cancer risk. This has never been systematically studied in animals or addressed in the Dihexa literature. The nootropic community routinely dismisses this concern as theoretical alarmism. But “we have not studied it” is not the same as “it is safe.” For a compound marketed for long-term cognitive enhancement, the absence of systematic toxicology and oncology data is a serious red flag.

Dihexa is legal to purchase as a research chemical in the United States, but remains an unapproved drug. It is unregulated, unmanufactured to pharmaceutical standards, and subject to contamination and mislabeling. It is also not in the WADA Prohibited List, though this is not an endorsement of safety or efficacy.

For individuals considering self-experimentation, the honest assessment is this: Dihexa has interesting mechanistic science behind it, but the evidence for human benefit is zero, the safety data are zero, and the cancer risk concern is non-trivial and unstudied. The potency claim, while scientifically valid in its narrow context, has been inflated beyond its meaning. Compare this to other nootropic compounds with human evidence, established dosing, and known risk-benefit profiles. The case for Dihexa does not hold up.

For researchers, Dihexa represents a valuable tool for studying HGF/c-Met signaling in neural plasticity. The original mechanistic work is solid. However, the translation to human cognition or therapeutics requires formal pharmacokinetic studies, toxicology, and ultimately, human clinical trials. This work has not begun, and there is no indication it will.

References

↑ Back to contents

Further Reading

↑ Back to contents

Peptide Biology and HGF/c-Met Signaling:

• Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends in Cell Biology. 1998;8(10):404–410.
• Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802–804.

Synaptic Plasticity and Learning:

• Kandel ER, Dudai Y, Mayford MR. The molecular and systems biology of memory. Cell. 2014;157(1):163–186.
• Bailey CH, Kandel ER, Harris KM. Structural basis of long-term potentiation in vertebrate synapses. Neuroscience. 2015;28:649–666.

Nootropic Research and Safety:

• Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Reviews. 2005;11(2):169–182.
• Gaspari S, Gaspari DA, DeLuca F, et al. Translation of rodent behavioral research into human clinical applications. Translational Psychiatry. 2020;10(1):160.

Cancer Biology and c-Met:

• Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Reviews Drug Discovery. 2008;7(6):504–516.
• Okigaki M, Davis C, Zhang X, et al. Endothelial progenitor cell mobilization and deterioration of chronic kidney disease involve Alt-HGF/c-Met pathway. American Journal of Pathology. 2009;174(6):2287–2296.

Regulatory and Clinical Trial Design:

• Guidance for Industry: Pharmacokinetics Data. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 1987.
• International Council for Harmonisation. ICH Guidelines for Good Laboratory Practice. 2019.

Disclaimer

↑ Back to contents